Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Ivabradine — a selective and specific If inhibitor: efficacy and safety in stable angina

K. Fox*

Royal Brompton Hospital, London, U.K.

* Kim Fox, Royal Brompton Hospital, Sydney Street, London, U.K.

Abstract

Aims To assess the antianginal and anti-ischaemic efficacy and safety of ivabradine in patients with stable angina.

Methods and results A total of 360 patients with stable angina were randomly assigned, in a double-blind fashion, to receive placebo or ivabradine 2.5 mg twice daily, 5 mg twice daily or 10 mg twice daily for 2 weeks. Patients voluntarily continued treatment (ivabradine 10 mg twice daily) in a 2- to 3-month, open-label extension period; this was followed by a randomized withdrawal period in which patients received ivabradine 10 mg twice daily or placebo for 1 week. Ivabradine was well tolerated, and no rebound phenomena were observed on treatment withdrawal. Dose-dependent significant reductions in heart rate were achieved at all dose levels (). Ivabradine 5 and 10 mg twice daily significantly increased time to 1-mm ST-segment depression () and time to limiting angina on exercise tolerance testing. Patients continuing on ivabradine during the withdrawal period maintained the improvements in exercise tolerance test criteria, whereas those who received placebo showed significant deterioration.

Conclusion Ivabradine (Procoralan®, Servier, Neuilly-sur-Seine, France) — a selective and specific inhibitor of the If (cardiac pacemaker, or ‘funny’) current — is a well-tolerated heart rate lowering agent with antianginal and anti-ischaemic efficacy in patients with stable angina. Results from the present study suggest that ivabradine could be a valuable alternative to current angina therapies.

Key Words: Exercise tolerance test • Heart rate • Ischaemia • Ivabradine • Stable angina • ST-segment depression


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi
Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients
Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.